Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone versus methylprednisolone for hospitalized COVID-19
IRCT20210223050466N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dexamethasone and methylprednisolone in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: Mortality after 28 days, Length of hospital stay and 8 more. Started Mar 2021; status: completed.
02
Drugs
dexamethasonemethylprednisolone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20210223050466N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210223050466N1.